<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973504</url>
  </required_header>
  <id_info>
    <org_study_id>TRA-207</org_study_id>
    <nct_id>NCT01973504</nct_id>
  </id_info>
  <brief_title>Phase 2c Dose Comparison Study of MP4OX in Trauma</brief_title>
  <official_title>A Multi-center, Multinational, Randomized, Double-blind, Controlled, Dose Comparison Study to Evaluate Safety and Efficacy of MP4OX Plus Standard Treatment, in Severely Injured Trauma Subjects With Lactic Acidosis Due to Hemorrhagic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sangart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sangart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MP4OX is being developed as an ischemic rescue therapy to perfuse and oxygenate tissues at
      risk during hemorrhagic shock. MP4OX is a pegylated hemoglobin-based colloid designed to
      improve perfusion and target delivery of oxygen to ischemic tissues. This study will evaluate
      safety and efficacy of MP4OX treatment, in addition to standard therapy, in trauma patients
      suffering from lactic acidosis due to severe hemorrhagic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute trauma, including both blunt and penetrating injury, is often associated with
      uncontrolled bleeding that leads to hemorrhagic shock. During shock, inadequate blood flow
      results in local ischemia and tissue hypoxia (insufficient oxygenation) of critical organs
      with resulting lactic acidosis. More than 10% of trauma victims who reach hospital alive will
      die, and many will suffer from organ failure. The primary goal when treating traumatic
      hemorrhage is to control blood loss, support ventilation and oxygenation, and maintain
      cardiovascular function to maintain organ perfusion.

      Despite optimal care, organ dysfunction is present in many patients as evidenced by
      persistent lactic acidosis. Blood transfusions are intended to improve circulation of
      oxygen-carrying red blood cells, but are frequently insufficient, even when the hemoglobin
      level is optimized. The severity of lactic acidosis in trauma victims has also been shown to
      correlate with worse outcome.

      Support for the proposed application for MP4OX as a therapeutic adjunct to standard treatment
      of severe hemorrhage shock, is based on multiple preclinical studies in different animal
      models of hemorrhagic shock resuscitation. These preclinical studies demonstrated that
      survival was greater and restoration of acid-base status and hemodynamics were improved with
      MP4OX. The benefits of MP4OX in animals were observed with or without co-administration of
      autologous blood, demonstrating that red cell transfusion alone was insufficient, and that
      the effects of MP4OX were additive.

      The hypothesis for the current study is that MP4OX will enhance perfusion and oxygenation of
      ischemic organs and thereby prevent and reduce the duration of organ failure and improve
      morbidity and mortality outcome measures.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sangart ceased operations
  </why_stopped>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects discharged from hospital through Day 28 and alive at the Day 28 Follow up visit</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital-free, ICU-free, and Ventilator-free days</measure>
    <time_frame>Through 28 and 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects remaining in hospital, ICU or on ventilator</measure>
    <time_frame>Through 28 and 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in hospital, in ICU, or on Ventilator</measure>
    <time_frame>Through 28 and 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>At 48 hours and 28 or 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge from ICU, hospital discharge, or liberation from ventilation</measure>
    <time_frame>Through 28 or 60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Time to Complete Organ Failure Resolution (CTCOFR)</measure>
    <time_frame>Day 21</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Daily modified Denver Score</measure>
    <time_frame>Day 7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients with persistent renal dysfunction</measure>
    <time_frame>Day 60</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of ICU stay for survivors</measure>
    <time_frame>Day 28 and Day 60</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects who normalize lactate</measure>
    <time_frame>4 hours</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Trauma</condition>
  <condition>Hemorrhagic Shock</condition>
  <condition>Lactic Acidosis</condition>
  <arm_group>
    <arm_group_label>MP4OX 500-mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500-mL dose of MP4OX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MP4OX 750-mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>750-mL dose of MP4OX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Standard crystalloid Keep Vein Open (KVO) infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP4OX</intervention_name>
    <description>4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution</description>
    <arm_group_label>MP4OX 500-mL</arm_group_label>
    <arm_group_label>MP4OX 750-mL</arm_group_label>
    <other_name>Hemoglobin pegylated</other_name>
    <other_name>MalPEG-Hb</other_name>
    <other_name>MP4</other_name>
    <other_name>PEG-Hb</other_name>
    <other_name>Pegylated-Hb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Crystalloid solution IV infusion drip to keep vein open</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Keep vein open (KVO) infusion</other_name>
    <other_name>Sham infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Trauma injury (blunt and/or penetrating) resulting in lactic acidosis due to
             hemorrhagic shock

          -  Acidosis (blood lactate level ≥ 5 mmol/L; equivalent to 45 mg/dL)

        Exclusion Criteria:

          -  Massive injury incompatible with life

          -  Normalization of lactate prior to dosing (≤ 2.2 mmol/L)

          -  Evidence of severe traumatic brain injury (TBI) as defined by ANY one of the
             following: Known non-survivable head injury or open brain injury; Known AIS (head
             region) ≥ 4 by an appropriate imaging methodology; Contemplated CNS surgery; Abnormal
             physical exam indicative of severe CNS or any spinal cord injury above T5 level; or
             Glasgow Coma Score (GCS) = 3, 4 or 5.

          -  Cardiac arrest prior to randomization

          -  Known age below the legal age for consenting

          -  Estimated time from injury to randomization &gt; 4 hours

          -  Estimated time from hospital admission to randomization &gt; 2 hours

          -  Known pregnancy

          -  Use of any oxygen carrier other than RBCs

          -  Known previous participation in this study

          -  Professional or ancillary personnel involved with this study

          -  Known receipt of any investigational drug(s) within 30 days prior to study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Brohi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal London Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank V. Booth, BCh, FACS</last_name>
    <role>Study Chair</role>
    <affiliation>Sangart, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme University Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina de S. J. Do Rio Preto</name>
      <address>
        <city>São José do Rio Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitário, Centro de Estudos em Emergências em Saúde, USP Ribeirão Preto</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo - FMUSP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHRU Lille</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der Rheinisch-Westfälische Technische Hochschule Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Virchow Klinikum Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln gGmbH Krankenhaus Merheim</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.-W.-Goethe-Universität Frankfurt a.M.</name>
      <address>
        <city>Franfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG Klinik Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Be'er-Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organization, Hadassah University Hospital, Ein-Karem</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital Ullevaal</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netcare Union Hospital</name>
      <address>
        <city>Alberton</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vincent Palotti Dr Christiaan Barnard Memorial Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Maxeke Johannesburg Academic Hospita</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netcare Milpark Hospital</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>South Africa</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.sangart.com</url>
    <description>Sangart Inc. (San Diego, CA) web site [Study SPONSOR]</description>
  </link>
  <reference>
    <citation>Cole RH, Vandegriff KD. MP4, a vasodilatory PEGylated hemoglobin. Adv Exp Med Biol. 2011;701:85-90. doi: 10.1007/978-1-4419-7756-4_12.</citation>
    <PMID>21445773</PMID>
  </reference>
  <reference>
    <citation>Young MA, Lohman J, Malavalli A, Vandegriff KD, Winslow RM. Hemospan improves outcome in a model of perioperative hemodilution and blood loss in the rat: comparison with hydroxyethyl starch. J Cardiothorac Vasc Anesth. 2009 Jun;23(3):339-47. doi: 10.1053/j.jvca.2008.08.006. Epub 2008 Oct 22.</citation>
    <PMID>18948027</PMID>
  </reference>
  <reference>
    <citation>Vandegriff KD, Winslow RM. Hemospan: design principles for a new class of oxygen therapeutic. Artif Organs. 2009 Feb;33(2):133-8. doi: 10.1111/j.1525-1594.2008.00697.x.</citation>
    <PMID>19178457</PMID>
  </reference>
  <reference>
    <citation>Vandegriff KD, Malavalli A, Mkrtchyan GM, Spann SN, Baker DA, Winslow RM. Sites of modification of hemospan, a poly(ethylene glycol)-modified human hemoglobin for use as an oxygen therapeutic. Bioconjug Chem. 2008 Nov 19;19(11):2163-70. doi: 10.1021/bc8002666.</citation>
    <PMID>18837531</PMID>
  </reference>
  <reference>
    <citation>Svergun DI, Ekström F, Vandegriff KD, Malavalli A, Baker DA, Nilsson C, Winslow RM. Solution structure of poly(ethylene) glycol-conjugated hemoglobin revealed by small-angle X-ray scattering: implications for a new oxygen therapeutic. Biophys J. 2008 Jan 1;94(1):173-81. Epub 2007 Sep 7.</citation>
    <PMID>17827244</PMID>
  </reference>
  <reference>
    <citation>Cole RH, Vandegriff KD, Szeri AJ, Savaş O, Baker DA, Winslow RM. A quantitative framework for the design of acellular hemoglobins as blood substitutes: implications of dynamic flow conditions. Biophys Chem. 2007 Jun;128(1):63-74. Epub 2007 Mar 13.</citation>
    <PMID>17418478</PMID>
  </reference>
  <reference>
    <citation>Young MA, Riddez L, Kjellström BT, Bursell J, Winslow F, Lohman J, Winslow RM. MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine. Crit Care Med. 2005 Aug;33(8):1794-804.</citation>
    <PMID>16096458</PMID>
  </reference>
  <reference>
    <citation>Drobin D, Kjellstrom BT, Malm E, Malavalli A, Lohman J, Vandegriff KD, Young MA, Winslow RM. Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4). J Appl Physiol (1985). 2004 May;96(5):1843-53. Epub 2004 Jan 16.</citation>
    <PMID>14729723</PMID>
  </reference>
  <reference>
    <citation>Winslow RM, Lohman J, Malavalli A, Vandegriff KD. Comparison of PEG-modified albumin and hemoglobin in extreme hemodilution in the rat. J Appl Physiol (1985). 2004 Oct;97(4):1527-34. Epub 2004 Jun 18.</citation>
    <PMID>15208289</PMID>
  </reference>
  <reference>
    <citation>Vandegriff KD, Bellelli A, Samaja M, Malavalli A, Brunori M, Winslow RM. Kinetics of NO and O2 binding to a maleimide poly(ethylene glycol)-conjugated human haemoglobin. Biochem J. 2004 Aug 15;382(Pt 1):183-9.</citation>
    <PMID>15175010</PMID>
  </reference>
  <reference>
    <citation>Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM. Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics. Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1411-9. Epub 2003 Jun 12.</citation>
    <PMID>12805024</PMID>
  </reference>
  <reference>
    <citation>Vandegriff KD, Malavalli A, Wooldridge J, Lohman J, Winslow RM. MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion. 2003 Apr;43(4):509-16.</citation>
    <PMID>12662285</PMID>
  </reference>
  <reference>
    <citation>McCarthy MR, Vandegriff KD, Winslow RM. The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers. Biophys Chem. 2001 Aug 30;92(1-2):103-17.</citation>
    <PMID>11527583</PMID>
  </reference>
  <reference>
    <citation>Young MA, Riddez L, Kjellström BT, Winslow RM. Effect of maleimide-polyethylene glycol hemoglobin (MP4) on hemodynamics and acid-base status after uncontrolled hemorrhage in anesthetized swine: comparison with crystalloid and blood. J Trauma. 2007 Dec;63(6):1234-44. doi: 10.1097/TA.0b013e31815bd7b0.</citation>
    <PMID>18212644</PMID>
  </reference>
  <reference>
    <citation>Wettstein R, Tsai AG, Erni D, Winslow RM, Intaglietta M. Resuscitation with polyethylene glycol-modified human hemoglobin improves microcirculatory blood flow and tissue oxygenation after hemorrhagic shock in awake hamsters. Crit Care Med. 2003 Jun;31(6):1824-30.</citation>
    <PMID>12794426</PMID>
  </reference>
  <reference>
    <citation>Husain FA, Martin MJ, Mullenix PS, Steele SR, Elliott DC. Serum lactate and base deficit as predictors of mortality and morbidity. Am J Surg. 2003 May;185(5):485-91.</citation>
    <PMID>12727572</PMID>
  </reference>
  <reference>
    <citation>Régnier MA, Raux M, Le Manach Y, Asencio Y, Gaillard J, Devilliers C, Langeron O, Riou B. Prognostic significance of blood lactate and lactate clearance in trauma patients. Anesthesiology. 2012 Dec;117(6):1276-88. doi: 10.1097/ALN.0b013e318273349d.</citation>
    <PMID>23168430</PMID>
  </reference>
  <reference>
    <citation>McNelis J, Marini CP, Jurkiewicz A, Szomstein S, Simms HH, Ritter G, Nathan IM. Prolonged lactate clearance is associated with increased mortality in the surgical intensive care unit. Am J Surg. 2001 Nov;182(5):481-5.</citation>
    <PMID>11754855</PMID>
  </reference>
  <reference>
    <citation>Abramson D, Scalea TM, Hitchcock R, Trooskin SZ, Henry SM, Greenspan J. Lactate clearance and survival following injury. J Trauma. 1993 Oct;35(4):584-8; discussion 588-9.</citation>
    <PMID>8411283</PMID>
  </reference>
  <reference>
    <citation>Tsai AG, Cabrales P, Manjula BN, Acharya SA, Winslow RM, Intaglietta M. Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood. 2006 Nov 15;108(10):3603-10. Epub 2006 Jul 20.</citation>
    <PMID>16857991</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2013</study_first_posted>
  <last_update_submitted>October 25, 2013</last_update_submitted>
  <last_update_submitted_qc>October 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trauma</keyword>
  <keyword>Hemorrhagic shock</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Lactic acidosis</keyword>
  <keyword>Oxygen therapeutics</keyword>
  <keyword>Oxygen carriers</keyword>
  <keyword>Ischemic rescue therapy</keyword>
  <keyword>Hemoglobin solutions</keyword>
  <keyword>PEGylated hemoglobin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Shock, Hemorrhagic</mesh_term>
    <mesh_term>Acidosis, Lactic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

